Quintiles Transitional Holdings Inc. (NYSE:Q) – Investment analysts at William Blair boosted their FY2017 EPS estimates for Quintiles Transitional Holdings in a report issued on Friday. William Blair analyst J. Kreger now anticipates that the medical research company will earn $4.61 per share for the year, up from their previous estimate of $4.57. William Blair currently has a “Outperform” rating and a $93.42 target price on the stock. William Blair also issued estimates for Quintiles Transitional Holdings’ Q4 2017 earnings at $1.33 EPS, Q2 2018 earnings at $1.27 EPS, Q3 2018 earnings at $1.37 EPS, Q4 2018 earnings at $1.53 EPS, FY2018 earnings at $5.36 EPS, FY2019 earnings at $6.08 EPS and FY2020 earnings at $6.90 EPS.

Quintiles Transitional Holdings (NYSE:Q) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. Quintiles Transitional Holdings had a net margin of 0.58% and a return on equity of 12.60%. The business had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the prior year, the business posted $1.00 earnings per share. The company’s revenue was up 77.6% on a year-over-year basis.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/30/quintiles-transitional-holdings-inc-forecasted-to-earn-fy2017-earnings-of-4-61-per-share-q.html.

Q has been the topic of a number of other reports. Barclays PLC set a $100.00 target price on shares of Quintiles Transitional Holdings and gave the stock a “buy” rating in a report on Friday, August 4th. Zacks Investment Research downgraded shares of Quintiles Transitional Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. KeyCorp restated a “buy” rating and issued a $100.00 target price on shares of Quintiles Transitional Holdings in a report on Sunday, September 24th. Jefferies Group LLC restated a “hold” rating and issued a $94.00 target price on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $92.00 target price (up from $87.00) on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $99.41.

Shares of Quintiles Transitional Holdings (NYSE Q) opened at 107.66 on Monday. The stock has a market capitalization of $23.31 billion, a price-to-earnings ratio of 312.06 and a beta of 0.62. The firm’s 50-day moving average is $97.62 and its 200 day moving average is $90.51. Quintiles Transitional Holdings has a 52-week low of $70.10 and a 52-week high of $108.43.

A number of institutional investors have recently added to or reduced their stakes in Q. Fiduciary Trust Co. purchased a new stake in Quintiles Transitional Holdings in the 2nd quarter valued at about $105,000. GWM Advisors LLC purchased a new stake in Quintiles Transitional Holdings in the 2nd quarter valued at about $122,000. Korea Investment CORP lifted its position in shares of Quintiles Transitional Holdings by 142.5% in the 2nd quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after purchasing an additional 805 shares during the period. Citigroup Inc. lifted its position in shares of Quintiles Transitional Holdings by 15.5% in the 2nd quarter. Citigroup Inc. now owns 1,858 shares of the medical research company’s stock worth $167,000 after purchasing an additional 250 shares during the period. Finally, Bbva Compass Bancshares Inc. lifted its position in shares of Quintiles Transitional Holdings by 4.2% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 2,204 shares of the medical research company’s stock worth $197,000 after purchasing an additional 88 shares during the period. 93.27% of the stock is owned by institutional investors.

In other Quintiles Transitional Holdings news, major shareholder Cpp Investment Board Private H sold 6,748,026 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total value of $640,185,226.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ari Bousbib sold 92,160 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $90.35, for a total transaction of $8,326,656.00. Following the completion of the sale, the insider now directly owns 1,082,919 shares of the company’s stock, valued at $97,841,731.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,208,382 shares of company stock valued at $1,362,839,475. 6.40% of the stock is owned by corporate insiders.

About Quintiles Transitional Holdings

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Earnings History and Estimates for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.